APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bi-Specific Antibodies Therapy

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Bi-Specific Antibodies Therapy Industry Growth and Trends Forecast to 2032

28 December 2025101 pages

Choose your research edition.

Industry ResearchBi-Specific Antibodies Therapy Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Bi-Specific Antibodies Therapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Bi-Specific Antibodies Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bi-Specific Antibodies Therapy Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Bi-Specific Antibodies Therapy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

According to APO Research, the global Bi-Specific Antibodies Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Bi-Specific Antibodies Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Bi-Specific Antibodies Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bi-Specific Antibodies Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Bi-Specific Antibodies Therapy market include Alphamab Co. Ltd, Genmab, Lindis Biotech, MacroGenics, Inc, AstraZeneca, AbbVie, Amgen, Pfizer and Akeso, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Bi-Specific Antibodies Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Bi-Specific Antibodies Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Bi-Specific Antibodies Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Bi-Specific Antibodies Therapy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Bi-Specific Antibodies Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Bi-Specific Antibodies Therapy Market by Company

Alphamab Co. Ltd

Genmab

Lindis Biotech

MacroGenics, Inc

AstraZeneca

AbbVie

Amgen

Pfizer

Akeso, Inc.

Roche

Johnson & Johnson

Sanofi

Bi-Specific Antibodies Therapy Segment by Type

Fragment-Based Antibodies

IgG-Based Antibodies

Bi-Specific Antibodies Therapy Segment by Application

Cancer

Haemophilia

Other Non-Cancer Diseases

Bi-Specific Antibodies Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Bi-Specific Antibodies Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Bi-Specific Antibodies Therapy Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Bi-Specific Antibodies Therapy Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Bi-Specific Antibodies Therapy Market Share by Region (2021-2026) Table 4. Global Bi-Specific Antibodies Therapy Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Bi-Specific Antibodies Therapy Market Share by Region (2027-2032) Table 6. Global Bi-Specific Antibodies Therapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Bi-Specific Antibodies Therapy Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Bi-Specific Antibodies Therapy Market Size Share by Type (2021-2026) Table 9. Global Bi-Specific Antibodies Therapy Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Bi-Specific Antibodies Therapy Market Size Share Forecasted by Type (2027-2032) Table 11. North America Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Bi-Specific Antibodies Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Bi-Specific Antibodies Therapy Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Bi-Specific Antibodies Therapy Market Size Share by Application (2021-2026) Table 24. Global Bi-Specific Antibodies Therapy Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Bi-Specific Antibodies Therapy Market Size Share Forecasted by Application (2027-2032) Table 26. North America Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Bi-Specific Antibodies Therapy Industry Trends Table 37. Bi-Specific Antibodies Therapy Industry Drivers Table 38. Bi-Specific Antibodies Therapy Industry Opportunities and Challenges Table 39. Bi-Specific Antibodies Therapy Industry Restraints Table 40. Global Bi-Specific Antibodies Therapy Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Bi-Specific Antibodies Therapy Revenue Market Share by Company (2021-2026) Table 42. Global Bi-Specific Antibodies Therapy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Bi-Specific Antibodies Therapy Key Company Headquarters & Area Served Table 44. Global Bi-Specific Antibodies Therapy Company, Product Type & Application Table 45. Global Bi-Specific Antibodies Therapy Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Bi-Specific Antibodies Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Alphamab Co. Ltd Company Information Table 49. Alphamab Co. Ltd Business Overview Table 50. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio Table 52. Alphamab Co. Ltd Recent Development Table 53. Genmab Company Information Table 54. Genmab Business Overview Table 55. Genmab Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Genmab Bi-Specific Antibodies Therapy Product Portfolio Table 57. Genmab Recent Development Table 58. Lindis Biotech Company Information Table 59. Lindis Biotech Business Overview Table 60. Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio Table 62. Lindis Biotech Recent Development Table 63. MacroGenics, Inc Company Information Table 64. MacroGenics, Inc Business Overview Table 65. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio Table 67. MacroGenics, Inc Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio Table 72. AstraZeneca Recent Development Table 73. AbbVie Company Information Table 74. AbbVie Business Overview Table 75. AbbVie Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. AbbVie Bi-Specific Antibodies Therapy Product Portfolio Table 77. AbbVie Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Amgen Bi-Specific Antibodies Therapy Product Portfolio Table 82. Amgen Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Pfizer Bi-Specific Antibodies Therapy Product Portfolio Table 87. Pfizer Recent Development Table 88. Akeso, Inc. Company Information Table 89. Akeso, Inc. Business Overview Table 90. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio Table 92. Akeso, Inc. Recent Development Table 93. Roche Company Information Table 94. Roche Business Overview Table 95. Roche Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Roche Bi-Specific Antibodies Therapy Product Portfolio Table 97. Roche Recent Development Table 98. Johnson & Johnson Company Information Table 99. Johnson & Johnson Business Overview Table 100. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio Table 102. Johnson & Johnson Recent Development Table 103. Sanofi Company Information Table 104. Sanofi Business Overview Table 105. Sanofi Bi-Specific Antibodies Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Sanofi Bi-Specific Antibodies Therapy Product Portfolio Table 107. Sanofi Recent Development Table 108. North America Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Bi-Specific Antibodies Therapy Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Bi-Specific Antibodies Therapy Market Share by Country (2021-2026) Table 111. North America Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Bi-Specific Antibodies Therapy Market Share Forecast by Country (2027-2032) Table 113. Europe Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Bi-Specific Antibodies Therapy Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Bi-Specific Antibodies Therapy Market Share by Country (2021-2026) Table 116. Europe Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Bi-Specific Antibodies Therapy Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Country (2021-2026) Table 121. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Bi-Specific Antibodies Therapy Market Share Forecast by Country (2027-2032) Table 123. Latin America Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2021-2026) & (US$ Million) Table 125. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2021-2026) Table 126. Latin America Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Latin America Bi-Specific Antibodies Therapy Market Share Forecast by Country (2027-2032) Table 128. Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2021-2026) Table 131. Middle East & Africa Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East & Africa Bi-Specific Antibodies Therapy Market Share Forecast by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Bi-Specific Antibodies Therapy Product Image Figure 3. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Bi-Specific Antibodies Therapy Market Size (2021-2032) & (US$ Million) Figure 5. Global Bi-Specific Antibodies Therapy Market Share by Region: 2025 VS 2032 Figure 6. Global Bi-Specific Antibodies Therapy Market Share by Region (2021-2032) Figure 7. North America Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Fragment-Based Antibodies Image Figure 13. Global Fragment-Based Antibodies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. IgG-Based Antibodies Image Figure 15. Global IgG-Based Antibodies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Bi-Specific Antibodies Therapy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Bi-Specific Antibodies Therapy Market Share by Type 2025 VS 2032 Figure 18. North America Bi-Specific Antibodies Therapy Market Size Share by Type (2021-2032) Figure 19. Europe Bi-Specific Antibodies Therapy Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Share by Type (2021-2032) Figure 21. Latin America Bi-Specific Antibodies Therapy Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Bi-Specific Antibodies Therapy Market Size Share by Type (2021-2032) Figure 23. Cancer Image Figure 24. Global Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Haemophilia Image Figure 26. Global Haemophilia Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Other Non-Cancer Diseases Image Figure 28. Global Other Non-Cancer Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Bi-Specific Antibodies Therapy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Bi-Specific Antibodies Therapy Market Share by Application 2025 VS 2032 Figure 31. North America Bi-Specific Antibodies Therapy Market Size Share by Application (2021-2032) Figure 32. Europe Bi-Specific Antibodies Therapy Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Share by Application (2021-2032) Figure 34. Latin America Bi-Specific Antibodies Therapy Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Bi-Specific Antibodies Therapy Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Bi-Specific Antibodies Therapy Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Bi-Specific Antibodies Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Bi-Specific Antibodies Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Bi-Specific Antibodies Therapy Market Share by Country (2021-2032) Figure 41. Europe Bi-Specific Antibodies Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Bi-Specific Antibodies Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Bi-Specific Antibodies Therapy Market Share by Country (2021-2032) Figure 44. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Country (2021-2032) Figure 47. Latin America Bi-Specific Antibodies Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Bi-Specific Antibodies Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2021-2032) Figure 50. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Fragment-Based Antibodies
  • IgG-Based Antibodies
Applications
  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases
Companies covered
  • Alphamab Co. Ltd
  • Genmab
  • Lindis Biotech
  • MacroGenics, Inc
  • AstraZeneca
  • AbbVie
  • Amgen
  • Pfizer
  • Akeso, Inc.
  • Roche
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Bi-Specific Antibodies Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Bi-Specific Antibodies Therapy Market Size by Region (2021-2032)
  5. 1.4.1 Global Bi-Specific Antibodies Therapy Market Size by Region (2021-2026)
  6. 1.4.2 Global Bi-Specific Antibodies Therapy Market Size by Region (2027-2032)
  7. 1.5 Key Regions Bi-Specific Antibodies Therapy Market Size (2021-2032)
  8. 1.5.1 North America Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate (2021-2032)
2 Bi-Specific Antibodies Therapy Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Fragment-Based Antibodies
  3. 2.1.2 IgG-Based Antibodies
  4. 2.2 Global Bi-Specific Antibodies Therapy Market Size by Type
  5. 2.2.1 Global Bi-Specific Antibodies Therapy Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Bi-Specific Antibodies Therapy Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Bi-Specific Antibodies Therapy Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Bi-Specific Antibodies Therapy Market Size by Regions
  9. 2.3.1 North America Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Bi-Specific Antibodies Therapy Market Size Breakdown by Type (2021-2026)
3 Bi-Specific Antibodies Therapy Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Cancer
  3. 3.1.2 Haemophilia
  4. 3.1.3 Other Non-Cancer Diseases
  5. 3.2 Global Bi-Specific Antibodies Therapy Market Size by Application
  6. 3.2.1 Global Bi-Specific Antibodies Therapy Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Bi-Specific Antibodies Therapy Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Bi-Specific Antibodies Therapy Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Bi-Specific Antibodies Therapy Market Size by Regions
  10. 3.3.1 North America Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Bi-Specific Antibodies Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Bi-Specific Antibodies Therapy Industry Trends
  2. 4.2 Bi-Specific Antibodies Therapy Industry Drivers
  3. 4.3 Bi-Specific Antibodies Therapy Industry Opportunities and Challenges
  4. 4.4 Bi-Specific Antibodies Therapy Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Bi-Specific Antibodies Therapy Revenue (2021-2026)
  2. 5.2 Global Bi-Specific Antibodies Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Bi-Specific Antibodies Therapy Key Company Headquarters & Area Served
  4. 5.4 Global Bi-Specific Antibodies Therapy Company, Product Type & Application
  5. 5.5 Global Bi-Specific Antibodies Therapy Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Bi-Specific Antibodies Therapy Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Bi-Specific Antibodies Therapy Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Bi-Specific Antibodies Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Alphamab Co. Ltd
  2. 6.1.1 Alphamab Co. Ltd Company Information
  3. 6.1.2 Alphamab Co. Ltd Business Overview
  4. 6.1.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio
  6. 6.1.5 Alphamab Co. Ltd Recent Developments
  7. 6.2 Genmab
  8. 6.2.1 Genmab Company Information
  9. 6.2.2 Genmab Business Overview
  10. 6.2.3 Genmab Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Genmab Bi-Specific Antibodies Therapy Product Portfolio
  12. 6.2.5 Genmab Recent Developments
  13. 6.3 Lindis Biotech
  14. 6.3.1 Lindis Biotech Company Information
  15. 6.3.2 Lindis Biotech Business Overview
  16. 6.3.3 Lindis Biotech Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio
  18. 6.3.5 Lindis Biotech Recent Developments
  19. 6.4 MacroGenics, Inc
  20. 6.4.1 MacroGenics, Inc Company Information
  21. 6.4.2 MacroGenics, Inc Business Overview
  22. 6.4.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio
  24. 6.4.5 MacroGenics, Inc Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 AbbVie
  32. 6.6.1 AbbVie Company Information
  33. 6.6.2 AbbVie Business Overview
  34. 6.6.3 AbbVie Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 AbbVie Bi-Specific Antibodies Therapy Product Portfolio
  36. 6.6.5 AbbVie Recent Developments
  37. 6.7 Amgen
  38. 6.7.1 Amgen Company Information
  39. 6.7.2 Amgen Business Overview
  40. 6.7.3 Amgen Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Amgen Bi-Specific Antibodies Therapy Product Portfolio
  42. 6.7.5 Amgen Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Bi-Specific Antibodies Therapy Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Akeso, Inc.
  50. 6.9.1 Akeso, Inc. Company Information
  51. 6.9.2 Akeso, Inc. Business Overview
  52. 6.9.3 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio
  54. 6.9.5 Akeso, Inc. Recent Developments
  55. 6.10 Roche
  56. 6.10.1 Roche Company Information
  57. 6.10.2 Roche Business Overview
  58. 6.10.3 Roche Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Roche Bi-Specific Antibodies Therapy Product Portfolio
  60. 6.10.5 Roche Recent Developments
  61. 6.11 Johnson & Johnson
  62. 6.11.1 Johnson & Johnson Company Information
  63. 6.11.2 Johnson & Johnson Business Overview
  64. 6.11.3 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio
  66. 6.11.5 Johnson & Johnson Recent Developments
  67. 6.12 Sanofi
  68. 6.12.1 Sanofi Company Information
  69. 6.12.2 Sanofi Business Overview
  70. 6.12.3 Sanofi Bi-Specific Antibodies Therapy Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Sanofi Bi-Specific Antibodies Therapy Product Portfolio
  72. 6.12.5 Sanofi Recent Developments
7 North America
  1. 7.1 North America Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
  3. 7.3 North America Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
  3. 8.3 Europe Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
  3. 10.3 South America Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst